Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus

Código QR

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus

Seitaro Omoto,1 Takehito Taniura,2 Tohru Nishizawa,3 Takeshi Tamaki,3 Akira Shouzu,4 Shosaku Nomura3 1Division of Internal Medicine, Korigaoka Yukeikai Hospital, 2Division of Internal Medicine, Daiwa Hospital, 3First Department of Internal Medicine, Kansai Medical University, 4Division of Internal M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Omoto S, Taniura T, Nishizawa T, Tamaki T, Shouzu A,Nomura S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/5985824997e146b1b27fe4ccff80972e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Shannon A Miller, et al.
Publicado: (2009)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahr&eacute;n
Publicado: (2010)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Jonathan K Reynolds
Publicado: (2009)

Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Pamela Kushner
Publicado: (2010)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
por: Feher M, et al.
Publicado: (2013)

Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase&ndash;lowering effects of garlic in patients with type 2 diabetes mellitus with obesity
por: Kumar R, et al.
Publicado: (2013)

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
por: Lorber D
Publicado: (2014)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
por: Irons BK, et al.
Publicado: (2014)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated [Corrigendum]
por: Irons BK, et al.
Publicado: (2017)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
por: Mazzilli R, et al.
Publicado: (2015)

Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management
por: Nitzan O, et al.
Publicado: (2015)

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
por: Ohira M, et al.
Publicado: (2014)

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
por: Konya H, et al.
Publicado: (2013)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holl, et al.
Publicado: (2014)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review
por: Colosia AD, et al.
Publicado: (2013)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen AB, et al.
Publicado: (2013)

Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention
por: Alaa Badawi, et al.
Publicado: (2010)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Stanley Schwartz, et al.
Publicado: (2010)

Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage [Corrigendum]
por: Wilke T, et al.
Publicado: (2019)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Jason Seewoodhary, et al.
Publicado: (2010)

Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting
por: Ofori SN, et al.
Publicado: (2014)

Glucose estimation in the salivary secretion of diabetes mellitus patients
por: Abikshyeet P, et al.
Publicado: (2012)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements
por: Yang F, et al.
Publicado: (2015)

Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study
por: Penfornis A, et al.
Publicado: (2015)

Long-term (52&ndash;78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
por: Bays HE
Publicado: (2012)

Management of gestational diabetes mellitus
por: Annunziata Lapolla, et al.
Publicado: (2009)

Using the health action process approach to predict and improve health outcomes in individuals with type 2 diabetes mellitus
por: MacPhail M, et al.
Publicado: (2014)

Risk factors associated with metabolic syndrome in type 2 diabetes mellitus patients according to World Health Organization, Third Report National Cholesterol Education Program, and International Diabetes Federation definitions
por: Angel Rodr&iacute;guez, et al.
Publicado: (2010)

Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study
por: Usharani P, et al.
Publicado: (2013)

Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine
por: Ogedengbe OS, et al.
Publicado: (2015)

Mechanism linking diabetes mellitus and obesity
por: Al-Goblan AS, et al.
Publicado: (2014)

Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
por: Le TD, et al.
Publicado: (2020)

Evidence for the benefit of exercise therapy in patients with type 2 diabetes
por: Madden KM
Publicado: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012)

Red cell distribution width in type 2 diabetic patients
por: Nada AM
Publicado: (2015)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Gregory E Peterson
Publicado: (2009)